Effect of EGCG-rich green tea extract (GTE) on chronic inflammation and thrombogenic risk factors in type 2 DM patients

• Main Authors: Ya-chan Chao, 趙雅嬋
• Other Authors: Kung-chi Chan
• Format: Others
• Language: zh-TW
• Published: 2010
• Online Access: http://ndltd.ncl.edu.tw/handle/06672616659793552849

碩士 === 靜宜大學 === 食品營養研究所 === 98 === Hyperglycemia-induced oxidative damage plays an important role in the development of chronic complications in type 2 diabetic patients. The health benefits of green tea extract (GTE), including the antioxidative, hypoglycemic, and anti-inflammatory effects have been well-known. The purpose of this study was to investigate the effect of EGCG-rich GTE on chronic inflammation and thrombogenic risk factors in type 2 DM patients. Fifty-one type 2 DM patients were randomly assigned into four experimental groups in this double-blinded study. Treatment groups were placebo (300 mg/day cellulose), low GTE group (300 mg/day GTE), medium GTE group (600 mg /day GTE) and high GTE group (900 mg/day GTE), respectively. After 8 weeks’ supplement, concentration of fasting plasma glucose, HbA1c, MDA, von Willebrand factor and inflammatory markers, activity of coagulation factor, anticoagulation factors and fibrinolytic factor were measured. The results of this study showed that concentration of fasting glucose, HbA1c, MDA and activity of factor VII were decreased significantly (p<0.1) ; activity of AT-III were increased significantly (p<0.1) in high dose GTE group. Concentration of vWF were increased significantly (p<0.1) in placebo group, however, PAI-1 value was not affected by GTE supplement. Concentration of insulin, hs-CRP, IL-6, TNF-α, vWF and insulin resistance all tended to be decreased by GTE supplementation. In conclusion, supplementing 900 mg/day of EGCG-rich GTE may have beneficial effects to ameliorate oxidative stress, chronic inflammation, abnormal blood coagulation, and hence decrease thrombogenic risk in type 2 diabetic patients. Keywords: Type 2 diabetes mellitus, Green tea extract, EGCG, chronic inflammation, thrombogenic risk factors